Prosecution Insights
Last updated: July 17, 2026
Application No. 17/547,008

COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS

Final Rejection §112
Filed
Dec 09, 2021
Priority
Nov 15, 2016 — provisional 62/422,523 +3 more
Examiner
VALENROD, YEVGENY
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Massachusetts Eye and Ear Infirmary
OA Round
4 (Final)
72%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
734 granted / 1012 resolved
+12.5% vs TC avg
Strong +26% interview lift
Without
With
+25.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
38 currently pending
Career history
1049
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
48.6%
+8.6% vs TC avg
§102
13.4%
-26.6% vs TC avg
§112
7.7%
-32.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1012 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 10-11, 58, 59 and 67-71 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claims are indefinite because it is unclear what group constitutes the subject population to be treated. Claims are directed to a method of treating or preventing SVD in a subject having the SVD. Specifically, the limitation of the claim directed to prevention of SVD in a subject who already has SVD is unclear. Allowed claims Claims 60 and 64-66 are allowed. Closest art is Liu (US 9,446,048). Liu teaches administration of Ro24-7429 for treatment of leukemia. Lui is silent regarding efficacy of the agent in inhibiting, treating or preventing aberrant ocular angiogenesis in the claimed subject population. Conclusion Claims 1, 10-11, 58-60 and 64-71 are pending Claims 1, 10, 11, 58, 59 and 67-71 are rejected Claims 60 and 64-66 are allowed THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to YEVGENY VALENROD whose telephone number is (571)272-9049. The examiner can normally be reached Mon-Fri 9am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /YEVGENY VALENROD/Primary Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

Show 3 earlier events
Jul 29, 2025
Response Filed
Aug 18, 2025
Final Rejection mailed — §112
Oct 15, 2025
Response after Non-Final Action
Nov 18, 2025
Request for Continued Examination
Nov 25, 2025
Response after Non-Final Action
Dec 11, 2025
Non-Final Rejection mailed — §112
Mar 09, 2026
Response Filed
Jun 03, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12661355
COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION
3y 8m to grant Granted Jun 23, 2026
Patent 12611402
COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
3y 10m to grant Granted Apr 28, 2026
Patent 12611391
MATERIALS AND METHODS FOR IMPROVING LUNG FUNCTION AND FOR PREVENTION AND/OR TREATMENT OF RADIATION-INDUCED LUNG COMPLICATIONS
3y 5m to grant Granted Apr 28, 2026
Patent 12605374
METHODS FOR DRUG SCREENING AND COMPOSITIONS USEFUL FOR THE INHIBITION OF CELL PROLIFERATION AND/OR CELL SURVIVAL
3y 10m to grant Granted Apr 21, 2026
Patent 12590100
TETRAHYDRO-SPIROINDOLINE-PYRROLOPYRROLE-TRIONES INHIBITORS OF THE NRF2-BETA-TRCP INTERACTION FOR USE IN THE TREATMENT OF FATTY LIVER DISEASE
3y 0m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
72%
Grant Probability
98%
With Interview (+25.5%)
2y 6m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1012 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month